David T. Dicker

Brown University

H指数:47

被引数:6,595

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Corrigendum to “P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9” [Neoplasia, volume 23 (2021) 304325]

勘误：“P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9” [Neoplasia, volume 23 (2021) 304325]

Neoplasia

IF7.7

2025-11-140

OAAI

Reduction of TRAIL-Induced Mcl-1 and cIAP2 by c-Myc or Sorafenib Sensitizes Resistant Human Cancer Cells to TRAIL-Induced Death

TRAIL诱导的Mcl-1和cIAP2被c-Myc或Sorafenib降低，使耐药性人类癌细胞对TRAIL诱导的死亡更敏感。

Cancer Cell

IF44.5

2025-07-240

PRE

Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway (Vol 14, 99, 2015)

MOLECULAR CANCER

IF33.9

2024-10-180

OAAI

Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity

MOLECULAR AND CELLULAR BIOLOGY

IF2.7

2023-03-27234

OAAI

Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (Taxol)-exposed cells

MOLECULAR AND CELLULAR BIOLOGY

IF2.7

2023-03-27245

OAAI

Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer in vitro and in vivo

ONC201和TRAIL联合治疗子宫内膜癌的体内外抗肿瘤作用

CANCER BIOLOGY & THERAPY

IF4.6

2021-10-2512

OAAI

Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90

通过双重靶向CDK1或CDK4/6和HSP90，包括Rb缺陷肿瘤和VHL非依赖性HIF1α 蛋白酶体去稳定的抗癌功效

SCIENTIFIC REPORTS

IF3.9

2021-10-229

OAAI

A subset of CB002 xanthine analogs bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53

ELIFE

IF0

2021-07-299

P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9

通过ERK1/2和CDK9的ATF4转录调节，P53-independent p53突变肿瘤中p53途径的部分恢复

NEOPLASIA

IF7.7

2021-03-0118

OAAI

A subgroup of potent CB002 xanthine derivatives define a novel class of anti-cancer drugs that restore the p53 pathway in tumors with mutated p53 and target an S-phase checkpoint

CANCER RESEARCH

IF16.6

2020-08-150

PRE

Anti-tumor effect and HIF1α inhibition by combining CDK4 inhibitor with HSP90 inhibitor in various cancer types including Rb-deficient tumor cells

CANCER RESEARCH

IF16.6

2020-08-150

PRE

Synergistic inhibition of cancer cell viability and suppression of HIFI a by CDK4 inhibitors and HSP90 inhibitors across cancer types

CANCER RESEARCH

IF16.6

2019-07-010

PRE

Recombinant human TRAIL or a DR5 agonistic antibody convert the response of non-triple negative breast cancer cells to ONC201 from anti-proliferative to apoptotic

CANCER RESEARCH

IF16.6

2019-07-010

PRE

Newly identified p53-pathway restoring small molecule, CB002 analog #4 induces apoptosis and appears non-toxic in vivo

CANCER RESEARCH

IF16.6

2019-07-010

PRE

Anti-tumorigenic effect of ONC201 is enhanced by combination treatment with TRAIL or a DR5 agonist in endometrial cancer in vitro

CANCER RESEARCH

IF16.6

2019-07-012

PRE

Involvement of the miR-6883 family and the circadian rhythm gene PER1 in the DNA damage response (DDR) and chemosensitivity

CANCER RESEARCH

IF16.6

2018-07-010

PRE

Anti-cancer agent P306 restores p53 pathway through PUMA

CANCER RESEARCH

IF16.6

2018-07-010

PRE

Anti-cancer effect by combination treatment of CDK and HSP90 inhibitors through HIF1α inhibition

CANCER RESEARCH

IF16.6

2018-07-010

PRE

miR-3132 induces TRAIL and cell death in mutant p53-expressing cancer cells

CANCER RESEARCH

IF16.6

2018-07-010

PRE

Newly identified p53 pathway-restoring compound CB002 and its derivatives sensitize colorectal and multiple myeloma cancer cell lines to front-line cancer therapies

CANCER RESEARCH

IF16.6

2018-07-010

PRE

David T. Dicker

个人简介

教育背景

工作经历

荣誉奖项

研究方向